Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Purchases 5,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of Anixa Biosciences stock in a transaction dated Thursday, September 10th. The stock was acquired at an average cost of $2.76 per share, with a total value of $13,800.00. Following the transaction, the chief executive officer owned 662,000 shares of the company’s stock, valued at $1,827,120. This trade represents a 0.76% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Friday, July 31st, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.47 per share, for a total transaction of $17,350.00.
• On Friday, July 24th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.37 per share, with a total value of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $15,200.00.

Anixa Biosciences Trading Up 0.4%

NASDAQ ANIX opened at $2.76 on Friday. Anixa Biosciences Inc has a 1-year low of $2.32 and a 1-year high of $5.46. The company has a 50 day moving average of $3.33 and a 200-day moving average of $2.98. The company has a market cap of $93.90 million, a price-to-earnings ratio of -8.62 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). On average, equities research analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Finally, Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ANIX. NewEdge Advisors LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at approximately $33,000. Sanctuary Advisors LLC bought a new position in Anixa Biosciences in the 2nd quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Anixa Biosciences in the second quarter valued at approximately $29,000. Integrated Wealth Concepts LLC acquired a new stake in Anixa Biosciences in the second quarter valued at approximately $30,000. Finally, Cetera Investment Advisers bought a new stake in shares of Anixa Biosciences during the fourth quarter worth $35,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.